Pharmaceuticals, Biotechnology and Life Sciences
– First FDA-approved treatment designed to target both ROS1 and NTRK that also shows response in cancer that has spread…
Biomarck Pharmaceuticals has improved the Overall Response Rate (ORR) in the BIO-11006/SOC group compared to standard of care alone at 3 months in the Phase 2 study in NSCLC, which compares standard of care alone, to SOC plus BIO-11006 in 60 patients with stage 4.
Camurus will start with the Phase 3 study of once-monthly octreotide subcutaneous depot for treatment of acromegaly CAM2029.
Debiopharm has enrolled first patient in SMARTPLUS-106, a Phase lb/II study in patients failing prior PD-1/PD-L1 treatment in selected solid tumors.
WESTPORT, Conn.–(BUSINESS WIRE)–Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers through…
Punit Upadhyaya, Ph.D., SeniorScientist at Bicycle, will present at the 6th Annual PeptidesCongress in London.
Torque will test its Deep IL-15 Primed T Cells (TRQ-1501) with Merck, both as a single agent and in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in a Phase 1/2 study in multiple solid tumor indications.
ADC Therapeutics, an oncology drug discovery and development company, has dosed first patient in its Phase Ib clinical trial of ADCT-301 in patients with selected solid tumors that are locally advanced or metastatic.
Mundipharma EDO GmbH (EDO) has begun a US Phase 1/2 clinical study for tinostamustine (EDO-S101) in patients with advanced solid…
Evgen Pharma said Tuesday that its lead product, SFX-01, will be tested against triple negative breast cancer (TNBC) in new preclinical research at the Manchester Cancer Research Centre, UK.